EmphyCorp is a pharmaceutical drug discovery company that is primarily engaged in the discovering, commercializing and developing of new drug therapies for conditions that involve cardio pulmonary and respiratory diseases such as asthma, chronic obstructive pulmonary disease and cystic fibrosis. The company is currently focusing on the development of a new drug based upon their all-new and extremely innovative proprietary technology known as N115. Currently in clinical trials, N115's unique form of proprietary technology is attempting to successfully promote healing and treatment for conditions such as a pulmonary disease.
In addition to its clinical trials involving N115 and pulmonary diseases, EmphyCorp is engaged in conducting clinical trials regarding sodium pyruvate as a treatment for lung inflammation, cancer prevention and sarcodosis. Our company was founded to address the significant worldwide market and medical necessity for a safe, bona fide and effective method of therapy to treat pulmonary diseases while acting as both a bronchodilator and an aided anti-inflammatory agent. With great aspirations, our company believes that our proprietary technology, N115, will prove to be one of the safest and most effective forms of duel-acting therapy.
Please note that aside from our unique form of medical technology, we are a company that has retained a solidified reputation. EmphyCorp is one of the only companies to have ever been granted an F.D.A. designation (the EmphyCorp Orphan Drug) for a class of rare pulmonary diseases known as Interstitial Lung Disease (ILD).We are also one of the only companies to have been granted an F.D.A. designation for the use of N115 in the treatment of Cystic Fibrosis, or a class of pulmonary diseases.